Written By: Sylvia Miriyam Findlay
The Frost & Sullivan Enabling Technology of the Year Award is presented to a company that has developed a technology that can benefit or revolutionise the industry. The Award recipient has developed a system or enabling component of a system that removes a significant stumbling block in the development of technology.
Before considering the recipient of this award, the analyst team tracks market participants' technology innovations through ongoing market research, market interviews, and extensive secondary and technology research.
In addition to the methodology described above, there are specific criteria used to determine the final rankings. The recipient of this award has excelled based on one or more of the following criteria:
The 2006 Frost & Sullivan Enabling Technology award is presented to Debiotech for its innovative solutions in insulin pump industry. It has been recognized for its efforts in venturing into a market that has seen practically no developments over the years and is now aggressively attempting to revolutionize the insulin drug delivery market.
Debiotech was founded 16 years ago in 1990. With 40 employees in the organization, it focuses on the development of innovative drug delivery systems. It is a dynamic organization that incorporates cutting edge technologies to introduce innovative medical devices. Debiotech integrates the best R&D skills with successful collaboration of major organisations to cater to the healthcare industry.
Debiotech make use of proprietary MEMS technologies that enable it to bring Insulin NanoPump to the customer. This technology, by itself, offers a lot of advantages to Debiotech’s products. By having a significantly lower process time and bigger lot size as compared to the conventional insulin pumps, Debiotech has the ability to supply to even the most demanding of industries. Secondly, and more importantly, by making sure it is the first in Insulin Nano Pump, Debiotech has gone one up on the emerging competition from other MEMS technology based insulin delivery devices.
Debiotech technological edge can be attributed to many factors; but none as significant as its rich track record in innovation and knowledge management of the founders, which manifested itself in faster time-to-market and effective partnership with the best institutions in MEMS research.
A key issue with companies targeting replacement markets with disruptive products is the fact that the adoption curve could vary significantly as the time progresses. It is to Debiotech’s credit that they have identified this challenge and taken it head-on. Debiotech identified the fact that it needs to minimize the risk perception for customers and consequently has collaborated with a major pharmaceutical participant. Such measures go a long way in assuring customers of the value of the solution.
Debiotech’s two-pronged strategy is expected to have significant benefits. While the company wants to take on the established insulin pump market by replacing the conventional insulin pumps, it also wants to go beyond doing just that. By integrating the added features of increased insulin reservoir size and precise reproducibility of insulin dose resulting in accurate dosing regimen, Debiotech hopes to achieve twin objectives- add value to its customers by increasing device compliance and adding to its own growth by way of targeting a much larger market. Customers are likely to appreciate the simplicity of a solution, compatibility and can offer superior performance whilst delivering enhanced value that comes by way of integration of safety measures. Moreover, this is precisely where Debiotech has made sure it is positioning itself in the insulin pump market. Debiotech’s value-added integrated solutions are expected to provide customers cost-savings and performance benefits that have hitherto not been possible with the insulin pumps in the market.
It is an acknowledged fact that taking on entrenched markets is an extremely difficult task for absolute startups. However, Debiotech has shown that it now has a unique technology that is capable of delivering better value to customers. Frost & Sullivan recognizes the potential of Debiotech’s products at being disruptive to the extent of altering the mechanics of the insulin pumps markets and deems these efforts worthy of the 2006 Frost & Sullivan Enabling Technology of the Year Award.
Avenue de Sevelin, 28
CH-1004 Lausanne, Switzerland
Learn more :Insulin Pump>>
Debiotech S.A., Av. de Sévelin 28, 1004 Lausanne, Switzerland.
© Copyright 1995-2006 Debiotech S.A. All rights reserved.